SeqOnce Biosciences
About this raise
SeqOnce Biosciences, with a valuation of $25 million, is raising funds on Republic. It is an innovative DeepTech company with expertise in Next-Generation Sequencing (NGS), PCR-based applications (qPCR), and novel tech development. SeqOnce Biosciences aims to make sample preparation for gene sequencing more efficient and introduce new assay opportunities for respiratory pathogens, women’s health, and pathogen screening. The company has launched nine products, developed two new novel technologies, and generated $45 million in revenue to date. Christopher Angermayer and Joseph Dunham founded SeqOnce Biosciences in February 2014. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for capital expenditure, debt service, manufacturing expansion, hiring, and working capital.
Investment Overview
Committed $112,361 :
Deal Terms
Company & Team
Company
- Year Founded
- 2014
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- High
- Capital Intensity
- Low
Financials
- Revenue -43% YoY
- $1,300,000
- Monthly Burn
- $194,758
-
Runway
- 0.1 months
- Gross Margin
- 92%
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $881,831
- VC Backed?
- Yes
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
04/30/2025 | Republic | $25,000,000 | $112,361 | SAFE | Active | RegCF |